Biotech Short Interest NOV 2007 II (AMGN, BIIB, CELG, GENZ, GILD, IMCL, MEDX)

We’ve had a lot of biotech stocks see their shares get the wrath of news over recent days.  Now that the November-end NASDAQ Short Interest has been released, we wanted to see how the gains and losses were in short selling activity.  Here is the key short selling data on NASDAQ as of November 27, 2007 and Settlement Date of November 30, 2007:

STOCK (Ticker)        Shares Short    Change
Amgen (AMGN)         29,112,550      +10.89%   
Biogen Idec (BIIB)     6,648,180         (9.58%)   
Celgene (CELG)       25,751,400      +12.19%   
Genzyme (GENZ)      6,536,150        +12.36%
Gilead (GILD)            25,557,168        (1.59%)
Imclone (IMCL)          4,252,342         (13.49%)
Medarex (MEDX)        30,181,760       (7.72%)   

As a reminder, Biogen Idec was the one that Wall Street feels is close to being acquired because of its review being announced.   

Jon C. Ogg
December 11, 2007

Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.